Clinical trialNCT04380805CompletedPhase 2Interventional

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

SponsorAkesoEnrollment30Metastatic Cervical CancerRecurrent Cervical Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Leslie Randall, MD
Virginia Commonwealth University
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Monash Health
Clayton, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Ashford Cancer Centre Research
Adelaide, Australia
Blacktown Hospital
Blacktown, Australia
Icon Cancer Centre
Brisbane, Australia

New Zealand

Auckland City Hospital
Grafton, Auckland, New Zealand

United States

Womens Cancer Research Foundation
Newport Beach, California, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Brcr Medical Center
Plantation, Florida, United States
Augusta University Medical Center
Augusta, Georgia, United States
Illinois Cancer Specialists
Arlington Heights, Illinois, United States
Maryland Oncology Hematology (plum Orchard)
Silver Spring, Maryland, United States
Monter Cancer Center
Lake Success, New York, United States
the Blavatnik Family - Chelsea Medical Center at Mount Sinai
New York, New York, United States
Oncology Hematology Care Inc
Cincinnati, Ohio, United States
Oklahoma Cancer Specialists and Research Institute, Llc
Tulsa, Oklahoma, United States
Chattanooga'S Program in Women'S Oncology
Chattanooga, Tennessee, United States
Tennessee Oncology - Centennial Clinic
Nashville, Tennessee, United States
University of Texas Southwestern
Dallas, Texas, United States
Texas Oncology-Fort Worth Cancer Center
Fort Worth, Texas, United States
Lyndon B. Johnson Hospital (md Anderson)
Houston, Texas, United States
Texas Oncology (woodlands)
The Woodlands, Texas, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Virginia Commonwealth University
Richmond, Virginia, United States
Pacific Gynecology Specialists, P. C.
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AK104

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Jul 2020
Primary completion: 22 Dec 2022
Completion: 31 Jan 2023
Last update posted: 28 Feb 2025
Registered enrollment: 30
Registry id: NCT04380805

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.